Table 4.
Patient and Tumor Characteristics Cohort 2.
| Variable | Triple Negative | Not Triple Negative | P | |
|---|---|---|---|---|
| 98 | 545 | |||
| T stage | pT1 | 48 (49%) | 267 (50%) | 0.08 |
| pT2 | 47 (48%) | 220 (41%) | ||
| pT3 | 1 (1%) | 43 (8%) | ||
| pT4 | 1 (1%) | 6 (1%) | ||
| Margin status | marg− | 95 (97%) | 511 (94%) | 0.36 |
| marg+ | 1 (1%) | 21 (4%) | ||
| close < 2 mm | 2 (2%) | 10 (2%) | ||
| Node status | pN0 | 62 (64%) | 313 (59%) | 0.46 |
| pN1mi | 3 (3%) | 26 (5%) | ||
| pN1 | 23 (24%) | 128 (24%) | ||
| pN2 | 8 (8%) | 42 (8%) | ||
| pN3 | 1 (1%) | 25 (5%) | ||
| Surgery type | Mastectomy | 53 (55%) | 307 (57%) | 0.62 |
| Lumpectomy | 44 (45%) | 228 (43%) | ||
| Adjuvant chemotherapy | no ChT | 14 (14%) | 266 (49%) | <0.0001 |
| ChT | 84 (85%) | 279 (52%) | ||
| Grade | I | 5 (5%) | 91 (17%) | <0.0001 |
| II | 14 (15%) | 264 (50%) | ||
| III | 77 (80%) | 178 (33%) | ||
| RT | Yes | 55 (56%) | 318 (58%) | 0.68 |
| No | 43 (44%) | 227 (42%) | ||
| GARD whole breast/CW | 21 (12–58.6) | 21.9 (4.5–66.6) | 0.63 | |
| Age | 55 (25–82) | 61 (24–95) | 0.0006 | |
| Radiation breast or chest wall dose (Gy) | 46.8 (34–59.7) | 50 (9–64.8) | 0.69 | |
| Boost dose (Gy) | 14 (10−20) | 14 (3.8–20) | 0.35 | |
| Total radiation dose (Gy) | 46.8 (34–59.74) | 50 (9–64.8) | 0.7 | |
| RT boost | No boost | 60 (64%) | 359 (69%) | 0.31 |
| Boost | 34 (36%) | 160 (31%) | ||
| LVSI | No | 68 (76%) | 358 (74%) | 0.69 |
| Yes | 22 (24%) | 129 (26%) | ||
| RSI | 0.41 (0.08–0.61) | 0.38 (0.05–0.68) | 0.18 | |
*ChT = Chemotherapy; ***GARD = Genomically adjusted radiation dose; ****RT = Radiotherapy; *****LVSI = Lymphovascular space invasion; ******RSI = Radiosensitivity index.